Navigation Links
Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
Date:1/5/2012

EAST BRUNSWICK, N.J., Jan. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Noble Financial Capital Markets Eighth Annual Equity Conference on Tuesday, January 17, 2012 at 10:00 AM Eastern Time.  The conference will be held at the Seminole Hard Rock Hotel in Hollywood, Florida.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT - GContact:  Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan information@savient.com 

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006 

 


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
2. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
3. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
4. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
5. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
6. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
7. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
8. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
10. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
11. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2019)... ... December 06, 2019 , ... The ... research, recently unveiled its bold new initiative to kickstart MSA research collaborations. ... of life. , Infused by $3 million in new bequests earmarked for research ...
(Date:12/5/2019)... ... December 05, 2019 , ... nView, ... Maurice Rosenbaum to the role of Chief Product Officer. As the company expands ... changing dynamics of the behavioral health market into nView’s product and company growth ...
(Date:12/4/2019)... , ... December 04, 2019 , ... ... planning, has announced the Top 17 Master's in Organizational Psychology Degree Programs for ... colleges and universities in the nation. Each program is evaluated based on curriculum ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... 2019 , ... Lasair Aesthetic Health Sponsors Toys for Tots to Give Free Toys to Children ... Bring in Toys During the Holidays , Lasair Aesthetic Health is spreading holiday cheer again ... bring in a toy or toys worth more than 25-dollars, will get FIVE units of ...
(Date:12/6/2019)... ... , ... TIME For Kids (TFK) revealed the first-ever list of ... fun destinations that are tailored to the interests of kids. The list identifies The ... the list, TIME for Kids gathered nominations from its network of TFK Kid ...
(Date:12/5/2019)... , ... December 05, 2019 , ... Abide, the #1 ... 25 million times this year using Bible-based bedtime stories. Listeners have recovered from bad ... According to the Center for Disease Control, one third of Americans suffer from poor ...
(Date:12/5/2019)... ... December 05, 2019 , ... It’s been an impactful year ... help people embrace, achieve, and maintain a healthy lifestyle to giving generously to ... our mission of impacting world health, so it’s gratifying to look back on ...
(Date:12/4/2019)... ... December 04, 2019 , ... Now a ... protection from disruptions to cells and tissue and inflammation that leads to Jet ... is available in a dietary supplement product called Prepair™ . , Today, ...
Breaking Medicine News(10 mins):